$NEOS News
Last published 1y ago
- 1y agoNEOSApproval of Adzenys Xr-odt, Nda #204326 (Labeling)FDA Approved DrugsApproval Date: 09/23/2025; Drug Name: Adzenys Xr-odt, Nda #204326; Active Ingredients: AMPHETAMINE; Company: Neos Theraps; Submission Status: Approval; Submission Classification: Labeling; Application Number: 204326
- 1y agoNEOSApproval of Cotempla Xr-odt, Nda #205489 (Labeling)FDA Approved DrugsApproval Date: 09/23/2025; Drug Name: Cotempla Xr-odt, Nda #205489; Active Ingredients: METHYLPHENIDATE; Company: Neos Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 205489
- 4y agoNEOSApproval of Adzenys Er, Nda #204325 (Labeling)FDA Approved DrugsApproval Date: 02/25/2022; Drug Name: Adzenys Er, Nda #204325; Active Ingredients: AMPHETAMINE; Company: Neos Theraps Inc; Submission Status: Approval; Submission Classification: Labeling; Application Number: 204325
- 5y agoNEOSGlass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScienceGlobeNewswire– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
- 5y agoNEOSLeading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScienceGlobeNewswire– The Neos Therapeutics Board of Directors recommend stockholders vote “FOR” the transaction in advance of the virtual special meeting scheduled for March 18, 2021 at 10:00 a.m. Eastern Time – –...
- 5y agoHTGCDASHMASSACEV+10Hercules Capital Reports Fourth Quarter and Full-Year 2020 Financial ResultsBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December ...
- 5y agoNEOSAYTUAytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021GlobeNewswire– Record date for each Special Meeting of Stockholders is February 5, 2021 – – Upon merger closing, combined company will be renamed Aytu Biopharma, Inc. – ENGLEWOOD, Colo. and GRAND PRAIRIE,...
- 5y agoAYTUNEOSAytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021ACCESS Newswire- Record date for each Special Meeting of Stockholders is February 5, 2021 -
- 5y agoMTSCNEOSSPRQPRSPMoore Kuehn Encourages MTSC, SPRQ, NEOS, and PRSP Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
- 5y agoNEOSNeos Therapeutics to Present at H.C. Wainwright Virtual BioConnect ConferenceGlobeNewswireDALLAS and FORT WORTH, Texas, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 5y agoNEOSAYTUAytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue¹ Specialty Pharmaceutical CompanyGlobeNewswireMerger accelerates transformation to profitability, with estimated annualized cost synergies of $15M beginning FY 2022 Aytu adds Neos’ established, multi-brand ADHD portfolio, enhancing Aytu’s...
- 5y agoAYTUNEOSAytu BioScience and Neos Therapeutics Announce Definitive Merger Agreement, Creating a Combined $100M Revenue(1) Specialty Pharmaceutical CompanyACCESS NewswireAytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, and Neos Therapeutics, Inc. (NASDAQ:NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous system-focused products, today announced that they have entered into a definitive merger agreement pursuant to which ...
- 6y agoNEOSNeos Therapeutics Reports Third Quarter 2020 Financial ResultsGlobeNewswireDALLAS and FORT WORTH, Texas, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics to Host Third Quarter 2020 Financial and Operating Results Conference Call on November 9th, 2020GlobeNewswireDALLAS and FORT WORTH, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics to Present at Cantor Virtual Global Healthcare ConferenceGlobeNewswireDALLAS and FORT WORTH, Texas, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics Reports Second Quarter 2020 Financial ResultsGlobeNewswireDALLAS and FORT WORTH, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics to Host Second Quarter 2020 Financial and Operating Results Conference Call on August 10th, 2020GlobeNewswireDALLAS and FORT WORTH, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics to Present at the Jefferies Virtual Global Healthcare ConferenceGlobeNewswireDALLAS and FORT WORTH, Texas, May 26, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics Reports First Quarter 2020 Financial ResultsGlobeNewswire– Company announces reduction in force to streamline costs and accelerate the path to profitability, particularly in light of the business impact from the COVID-19 pandemic – – Company to host...
- 6y agoNEOSNeos Therapeutics Announces Issuance of New U.S. Methods of Use Patent for N-desethyloxybutyninGlobeNewswireDALLAS and FORT WORTH, Texas, April 09, 2020 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ: NEOS), a commercial-stage pharmaceutical company developing and manufacturing central nervous...
- 6y agoNEOSNeos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial ResultsGlobeNewswire– Full year 2019 net revenues increased by 29% and operating loss decreased by $33M – – Neos RxConnect rapidly expanded with ~500 pharmacies in network at year-end – – NT0502 Phase 1...
- 6y agoNEOSNEOS is a 2020 Best Places to Work in Connecticut HonoreePR NewswireNEOS has been named as an honoree for the Best Places to Work in Connecticut by the Best Companies Group and Hartford Business Journal. The honor...
- 7y agoNEOSNeos Therapeutics to Host Third Quarter 2019 Financial and Operating Results Conference Call on November 8, 2019GlobeNewswireDALLAS and FORT WORTH, Texas, Nov. 01, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery...
- 7y agoNEOSNeos Therapeutics to Present at Cantor Fitzgerald Global Healthcare ConferenceGlobeNewswireDALLAS and FORT WORTH, Texas, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical company utilizing its novel microparticle delivery...
- 7y agoNEOSNeos Therapeutics Reports Second Quarter 2019 Financial ResultsGlobeNewswire– Company to host conference call today at 8:30am EDT – DALLAS and FORT WORTH, Texas, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a commercial-stage pharmaceutical...
- 7y agoNEOSNeos Therapeutics, Inc. (NEOS) CEO Jerry McLaughlin on Q4 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 8y agoNEOSNeos Therapeutics' (NEOS) CEO Jerry McLaughlin on Q2 2018 Results - Earnings Call TranscriptEarnings Call Transcripts
- 9y agoNEOSNeos' (NEOS) CEO Vipin Garg on Q3 2017 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoNEOSNeos Therapeutics' (NEOS) CEO Vipin K. Garg on Q1 2016 Results - Earnings Call TranscriptEarnings Call Transcripts
- 10y agoNEOSNeos Therapeutics' (NEOS) CEO Vipin Garg on Q4 2015 Results - Earnings Call TranscriptEarnings Call Transcripts
- 11y agoHTGCNEOSEDGECERCU+4Hercules Announces Third Quarter 2015 Financial Results and Quarterly Dividend of $0.31 per ShareBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty financing provider to innovative venture growth stage companies backed by leading venture capital firms, today announced its financial results for the third quarter ended September 30, 2015.
- 11y agoHTGCNEOSSNPSHercules Announces Second Quarter 2015 Financial Results and Quarterly Dividend of $0.31 per ShareBusiness WirePALO ALTO, Calif.--(BUSINESS WIRE)--Hercules Technology Growth Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the leading specialty finance company focused on providing senior secured loans to high growth venture capital-backed companies in technology-related industries, including technology, biotechnology, life sciences, and energy & renewable technology, today announced its financial ...